tion of human insulin by bacteria. Such bacteria could provide a sure and consistent source of unlimited amounts of insulin. Whereas at present there is generally enough insulin for medical needs, the supply from animal sources may not keep up with the demand as the world's population increases and receives better health care. Furthermore, patients in whom animal insulins are significantly antigenic may benefit from treatment with human insulin. When these techniques first became possible in the early 1970's some biochemists expressed concern that inserting foreign DNA into bacteria might produce harmful organisms [2] . Some feared that genes responsible for cancer or for the production of toxins could be cloned accidentally, and that bacteria containing these genes might survive and become infectious. As a result, a number of agencies including the National Institutes of Health promulgated a series of guidelines which regulated the source and purity of DNA to be cloned, the type of bacterial DNA into which this could be inserted for cloning, the organisms that could receive such recombinant DNA, and the physical containment precautions to be observed in the laboratories [3] . Numerous experiments now indicate that these initial fears were probably unwarranted. Thus, experiments with cloned DNA of polyoma virus (a tumor-causing virus which is highly infective in mice) failed to demonstrate that infection could be induced in susceptible animals by E. coli harbouring recombinant polyoma DNA [4, 5] . Therefore, although certain restrictions remain in force, it is now possible to proceed with useful experiments.
Mammalian and bacterial cells synthesize proteins in similar fashions. DNA is transcribed by a complex polymerase into RNA. The sequence of nucleotides in the RNA is dictated by base pairing wherein adenine (A) pairs with thymidine (T) in RNA was prepared from rat pancreatic islet cells which contain mRNA coding for insulin. Insulin mRNA, like most mRNAs from higher organisms, is polyadenylated, so that it was among the mRNAs prepared by affinity chromatography on oligo (dT)-cellulose [12] . This mRNA was copied into single-stranded DNA complementary to it (cDNA) by reverse transcriptase from avian myelobtastosis virus [10, 11] . After alkali digestion of the mRNA template, the single-stranded cDNA was again reverse-transcribed into a double-stranded cDNA. This results in a hairpin loop because the first strand folds back on itself to initiate the synthesis of the second strand. The hairpin was opened and the singlestranded ends were partially digested with $I nuclease [13] , an enzyme which digests single-stranded but not double-stranded DNA. Any remaining single-stranded ends not destroyed by $1 were filled in by DNA potymerase I to yield "blunt-ended" cDNA. Synthetic DNA "linkers" containing the recognition sequence of the restriction enzyme Eco RI [14] were attached to the blunt-ended cDNA by DNA ligase from bacteriophage T4. The cDNA was then digested with Eco RI to yield cohesive termini suitable for ligation into a plasmid as shown in Figure 2 DNA or uridine (U) in RNA, and guanine (G) pairs with cytosine (C). Thus, the RNA contains bases that are "complementary" to those in the strand of DNA that was transcribed. The RNA may undergo further processing before it is used as messenger RNA (mRNA). The mRNA is translated into protein on ribosomes, where it directs the assembly of amino acids (carried to the ribosome by transfer RNA) into polypeptides.
The mRNA for insulin is translated into a polypeptide chain of 104 amino acids [6] termed preproinsulin. The first 23 amino acids, which constitute the "pre" sequence of the protein (sometimes also referred to as a "signal peptide") appear to facilitate the entry of the protein into the endoplasmic reticulum of the cell by hydrophobic interactions [7, 8] . The pre-sequence is cleaved from the protein during this process, leaving proinsulin within the endoplasmic reticulum. Further processing occurs when the C-peptide, a 30 amino acid sequence in the middie of the proinsulin chain, is excised by a trypsin-like proteolytic enzyme to yield the insulin secreted by the fi-cell. The A-chain (21 amino acids) and B-chain (30 amino acids) remain joined to one another by disulfide bonds which formed between cysteine residues during the initial synthesis of the protein. Thus, to obtain human insulin by recombinant DNA technology, it is first necessary to clone DNA coding for insulin and manipulate the bacteria to transcribe and translate that DNA into protein. That protein must then be processed so that it contains the A and B chains connected properly without a C-peptide or a pre-sequence.
The first step in the production of insulin by bacteria was achieved in 1977. Ullrich et al. [9] prepared mRNA from the islets of Langerhans of rats, then synthesized double-stranded DNA that was complementary to this mRNA using reverse transcriptase, a viral enzyme which makes DNA from a template of RNA (cDNA) [10, 11] . The details of these procedures are shown in Figure 1 . This DNA was then transferred to bacteria with the use of a plasmid. Plasmids (resistance-transfer factors) are circular pieces of DNA which will replicate in a bacterium independently of the bacterial chromosome. The insulin cDNA was inserted into the plasmid with the aid of restriction endoculeases. These enzymes recognize and cut specific sequences of DNA four to six nucleotides long (Fig. 2) '. The plasmid used contained a single site for the restriction enzyme Eco RI. This enzyme recognizes the sequence GAATI?C CITAAG and cleaves it to yield: .... Figure 1 , now has identical single-stranded sequences at each end. These sequences, the remains of the "linkers" following digestion with Eco RI, are the recognition sequence of Eco RI. A plasmid (a circular DNA molecule which confers antibiotic resistances to bacteria) was chosen which contained a single Eco RI site. The plasmid was opened with Eco RI and mixed with the cDNA. The complementary, cohesive Eco RI termini of the plasmid and of the cDNA aligned by hydrogen-bond base pairing, and the strands were sealed with DNA ligase. This chimeric plasmid was then put into suitable strains of E. coli which then replicated the plasmid 
Hybri di zati on
DScDNA Segment C22GCG ~ Recombi nant Plasmid Fig. 3 . Cloning of eDNA by "tailing". A bacterial plasmid such as pBR322, which has been specially designed for use in recombinant DNA experiments [17] , is cleaved with a restriction endonuclease such as Pst I. As there is only one Pst I site in pBR322, the cleavage results in a linear plasmid having short single-stranded (3)' ends as a result of the cleavage. A polymeric chain ("tail") of deoxyguanosine residues is added to these (3)' ends by terminal transferase, an enzyme which extends single-stranded (3)' ends [18] . Deoxycytosine residues are added to linear double-stranded eDNA in the same manner. The tailed eDNA and tailed plasmid are mixed, and the (3)' ends of poly(G) and poly(C) hybridize by base pairing, forming a stable, circular, recombinant plasmid. In practice, the tails of dC and dG are 15-30 nucleotides in length, forming very stable hybrids which do not need to be sealed by DNA ligase as shown in Figure 2 eDNA could bind by base pairing to the AATT.. on one end of the cleaved plasmid, and the AATF.. on the other end of the eDNA could bind to the . .T-FAA on the other end of the cleaved plasmid. The resulting recombinant DNA molecule was then inserted into a strain of E. coli which can only live in special laboratory environments [15] . A colony of E. coli containing the recombinant plasmid was selected and grown in order to prepare a large amount of plasmid DNA, all derived from the single original recombinant plasmid. The cloned DNA complementary to the mRNA for rat pre-proinsulin was excised with the Eco RI enzyme and its nucleotide sequence was determined. The cloned DNA contained the complete coding region of rat proinsulin, part of the pre-peptide sequence and the entire DNA sequence coding for an untranslated portion of the mRNA on its 3' terminal end. A year later, Villa-Komaroff et al., achieved I the next step, the creation of bacterial clones which actually synthesized proinsulin [16] . Beginning with mRNA from a rat insulinoma, these investigators synthesized eDNA as did Ullrich et al. Rather than completing the synthesis of the double-stranded eDNA with DNA polymerase I and adding restriction sites to the ends of the eDNA, as shown in Figure 1 , they added single-stranded "tails" of polymeric deoxycytidine to the (3') ends of a plasmid (pBR322) which had been opened at its single site recognized by the restriction endonuclease Chemically synthesized pieces of double-stranded DNA were designed to contain the information coding for all the amino acids in the A or B chain of human insulin. Each synthetic chain began with the nucleotide triplet coding for methionine and ended with two "stop" signals to terminate transcription of RNA. The synthetic genes were inserted into plasmids by inserting them into the gene for fi-galaetosidase distal to the site where synthesis of the mRNA for/3-galactosidase begins. These plasmids were put into bacteria, which were then grown in medium containing galactose, but no glucose. In order to metabolize galactose, the bacteria had to make fi-galactosidase, which was connected by a methionine residue to an insulin A or B chain. Bacterial proteins were prepared and cleaved with cyanogen bromide, which cleaves proteins only at methionine residues. The liberated A or B chains were partially purified by differential solubility, DEAE-cellulose chromatography, Sephadex G-75 gel filtration, and RP-8 reversed-phase column chromatography. The preparations of A and B chains were reduced, mixed, and oxidized to yield immunologically active insulin (Fig. 3) . When the plasmid and the cDNA were mixed, the single-stranded tails of dC on the cDNA hybridized by base pairing to the single-stranded tails of dG on the plasmid, thus inserting the cDNA into the plasmid. E. coli transformed with this recombinant plasmid were grown, and colonies harbouring insulin gene sequences were chosen as before.
The Pst I site in pBR322 lies within the plasmid gene coding for fi-lactamase, which permits the plasmid to confer penicillin resistance to host bacteria. Inserting insulin cDNA into this gene results in the creation of a fused gene. This results in the synthesis of a fused protein, part of which is comprised of the first 182 amino acids of fi-lactamase (penicillinase), while the remainder contains the amino acids of proinsulin. By analysing the bacterial colonies with a solid-phase radioimmunoassay [19] a clone was identified which synthesized immunoassayable rat proinsulin. The insulin secreted by these bacteria, however, is imperfect. It is fused to a large portion of the penicillinase molecule and it retains the C-peptide of insulin. Furthermore, it is rat, and not human insulin. However, the experiment was important because it demonstrated that recombinant DNA technology could be used to produce mammalian proteins such as insulin in bacteria.
While similar work with human insulinomas proceeded in several laboratories, Crea et al. [20] applied elaborate organic chemistry to the synthesis of insulin genes by purely chemical means. These investigators had previously created a totally synthetic gene for somatostatin and had achieved its expression in bacteria [21] . This proved that a synthetic gene could be designed from a known amino acid sequence and be propagated and expressed in bacteria even if the synthetic gene did not contain exactly the same nucleotide sequence found in the native gene. From the known amino acid sequence of insulin and the known genetic code, these workers designed a DNA sequence that would code for human insulin. Beginning with chemically-modified nucleotides, a library of 32 different nucleotide trimers was created. These trimers were then used to assemble 29 different oligo-deoxyribonucleotides, varying form 10 to 15 bases in length. These larger building blocks were then assembled into two different double-stranded DNA fragments, coding for the amino acids in the A and B chains, respectively. To facilitate their insertion into and excision from plasmid DNA, restriction enzyme sites were added to each end of the synthetic gene. Large quantities of each synthetic gene fragment were generated by cloning them in bacteria.
Goeddel et al. [22] then inserted the synthetic gene for the B-chain into a bacterial gene for fi-galactosidase, which had previously been cloned in a plasmid. Transcription of this fused gene resulted in the production of a fused protein consisting of fl-galactosidase and the insulin B-chain. The gene for the A chain was inserted into the fi-galactosidase gene in the same manner. When the synthetic A and B genes were designed, DNA coding for an extra methionine residue was placed at each 5' (amino terminal) end so that this amino acid would be inserted between the/3-galactosidase and insulin sequences. Cyanogen bromide, a proteolytic agent which cleaves proteins only at methionine residues, was then used to liberate the insulin chains and fragment the fi-galactosidase. The A and B chains, which contain no methionine, remained intact. The A and B chains were then partially purified, mixed, and joined by forming disulfide bonds, thus generating radioimmunoassayable insulin. These steps are outlined in Figure 4 . The A Chain preparation was purified further by high-performance liquid chromatography and found to have the amino acid composition of human insulin A chain, as predicted by the designed DNA sequence.
The work of Crea and Goeddel and their collaborators clearly demonstrated that human insulin can be made with the use of recombinant DNA technology. Since each amino acid may be coded by more than one array of three nucleotides, they could design and synthesize DNA sequences which code for human insulin chains and which could be manipulated and assembled conveniently. Even though the synthetic genes were not identical to the native gene sequences, the resulting insulin chains are chemically absolutely identical to native human insulin chains. By inserting the insulin genes into the gene for/3-galactosidase, Goedell et al. brought the production of insulin under the control of bacterial elements regulating the synthesis of/3-galactosidase. By growing the bacteria in glucose-free medium containing galactose, synthesis of both fi-galactosidase and insulin chains were induced, resulting in the production of 1.4 mg insulin/1 of bacteria. However, the A and B chains must still be separated cleanly from the fragmented fi-galactosidase, and must then be united efficiently into functional insulin. Although Goeddel et al. detected immunoassayable insulin, the procedure used for the union of the A and B chains was only 10-15% efficient. Thus, the production of separate A and B chains may not be the best approach to producing insulin in bacteria. Other groups are attempting the bacterial cloning of DNA sequences coding for the entire human proinsulin molecule, including the C-peptide. It is thought that retaining the C-peptide may help the proper folding of the polypeptide chain so that the A and B chains are properly oriented and form the appropriate disulfide bonds. The C-peptide could then be removed by tryptic cleavage. Another approach is to clone the entire gene for pre-insulin in a mammalian virus such as SV-40, rather than in a bacterial plasmid. Cultured cells infected with such a virus might then produce and secrete intact, functional, fully processed insulin. A further advantage of such an approach would be the greater ease of harvesting and purifying insulin from culture medium rather than from bacterial cells.
Regardless of which recombinant techniques are employed, human insulin produced by this technology will still have to undergo extensive testing for biologic activity and antigenicity before it is approved for general use. However, this work is commanding the attention of a large number of skilled investigators and is fuelled by ample resources from the drug industry. Hence, there appears little doubt that human insulin produced from recombinant DNA will be ready for animal and human testing in the near future.
